BOSTON, MA, United States of America

Cem Sievers

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: The General Hospital Corporation. Active years: 2024.


% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Cem Sievers: Innovator in Glioblastoma Treatment

Introduction

Cem Sievers is a notable inventor based in Boston, MA, who has made significant contributions to the field of medical research. His work primarily focuses on developing innovative treatments for drug-tolerant glioblastoma, a challenging form of brain cancer.

Latest Patents

Cem Sievers holds a patent for "Compositions and methods for treating drug-tolerant glioblastoma." This invention provides compositions and methods specifically designed for the treatment of drug-tolerant glioblastoma, particularly targeting glioblastoma stem cells. The methods involve contacting a glioblastoma stem cell with a platelet-derived growth factor receptor alpha inhibitor, along with one or more of a histone lysine demethylase inhibitor and a Notch inhibitor. He has 1 patent to his name.

Career Highlights

Cem Sievers is affiliated with The General Hospital Corporation, where he continues to advance his research and contribute to the medical community. His work is crucial in the ongoing battle against glioblastoma, a condition that poses significant treatment challenges.

Collaborations

Cem collaborates with esteemed colleagues such as Anoop P Patel and Bradley Bernstein, who share his commitment to improving treatment options for patients suffering from glioblastoma.

Conclusion

Cem Sievers is a dedicated inventor whose innovative approaches to treating drug-tolerant glioblastoma are paving the way for future advancements in cancer therapy. His contributions are vital in the quest for effective treatments for this aggressive disease.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…